Professor Colin Baigent is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology and Honorary Consultant in Cardiovascular Epidemiology. Professor Baigent is a Fellow of the Royal College of Physicians, the Faculty of Public Health, and the European Society of Cardiology. He was elected a Fellow of the Academy of Medical Sciences in 2019. Professor Baigent’s main scientific interests are: (i) the design and conduct of large-scale streamlined randomized trials, and (ii) in the use of collaborative meta-analyses of individual patient data from randomized trials for the prevention and treatment of cardiovascular disease, and for the study of adverse drug effects. He has led some of the world’s largest collaborative meta-analyses of randomized trials, typically with individual participant data, resulting in numerous landmark papers that have defined the effects of statin therapy (the Cholesterol Treatment Trialists’ [CTT] Collaboration), aspirin (and other antiplatelet drugs), fibrinolytic therapy (in both acute myocardial infarction and ischaemic stroke), and the cardiovascular hazards of non-steroidal anti-inflammatory drugs (NSAIDs). His group coordinated the Study of Heart and Renal Protection (SHARP), recruiting 9438 patients with CKD in 390 hospitals in 18 countries. This trial showed that simvastatin 20mg plus ezetimibe 10mg daily significantly reduced the risk of atherosclerotic events. His work helped to highlight the importance of non-atherosclerotic (structural) heart disease in CKD, and influenced the design of the ongoing EMPA-KIDNEY trial, a trial comparing empagliflozin versus placebo in 5000 patients with CKD which his group is coordinating in 8 countries. In addition to his own research, Professor Baigent contributes to research governance by chairing numerous trial steering committees and data monitoring committees, and is vice-chair of the British Heart Foundation Clinical Studies Committee. He co-chaired the recent (2019) revision of the ESC/EAS Guidelines on the Management of Dyslipidaemia, and is Chair-elect of the ESC Committee for Practice Guidelines.